An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it ‘odd’
AstraZeneca shares were slumping while Bristol-Myers Squibb’s stock was jumping on Monday on reported deal talks. But the big question is why these two pharmaceutical giants would want to come together in the first place.
Covered in this story
What has happened since
- Bristol Myers Squibb is down 10.2% since this was published, 63 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $AZN.L yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AstraZeneca →Summary aggregated from MarketWatch's public RSS feed. The full reporting belongs to MarketWatch — please read it on their site.